No abstract available
Keywords:
anti-CTLA-4; COVID-19; SARS-CoV-2; anti-PD-1; anti-PD-L1; cancer patients; immune checkpoint inhibitors; immunotherapy; tocilizumab; viral infection.
Publication types
-
Editorial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Betacoronavirus*
-
COVID-19
-
Coronavirus Infections* / etiology
-
Coronavirus Infections* / immunology
-
Coronavirus Infections* / physiopathology
-
Cytokine Release Syndrome
-
Disease Progression
-
Humans
-
Immunotherapy / adverse effects*
-
Neoplasms* / complications
-
Neoplasms* / immunology
-
Neoplasms* / therapy
-
Pandemics*
-
Pneumonia, Viral* / etiology
-
Pneumonia, Viral* / immunology
-
Pneumonia, Viral* / physiopathology
-
SARS-CoV-2
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
tocilizumab